---
schema_version: "secwatch.filing_event.v1"
accession: "0001804220-21-000023"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2021-08-05T23:59:59+00:00"
generated_at: "2026-06-29T22:09:33.465920+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Regeneron Q2 revenue up 163% to $5.14B; GAAP EPS $27.97; EYLEA sales record $1.42B

## Summary
- Total revenues $5.14B (+163% YoY) including $2.59B REGEN-COV; core revenue ex-REGEN-COV +22%.
- GAAP diluted EPS $27.97 vs $7.61 in Q2 2020; non-GAAP diluted EPS $25.80 vs $7.16.
- EYLEA US net sales record $1.42B (+28% YoY); Dupixent global net sales $1.50B (+59% YoY, recorded by Sanofi).
- REGEN-COV: $2.59B US sales from 1.25M doses; EUA expanded for prophylaxis; Japan full approval; RECOVERY trial showed 20% mortality reduction in seronegative.
- Pipeline: Dupixent Phase 3 CSU positive; Libtayo Phase 3 NSCLC stopped early for survival benefit; $1.8B Tarrytown campus expansion over 6 years.

## SEC filing metadata
- accession: 0001804220-21-000023
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2021-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000180422021000023/0001804220-21-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000180422021000023/regn-20210805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001804220-21-000023
- JSON: https://secwatch.observer/filing/0001804220-21-000023.json
- Plain text: https://secwatch.observer/filing/0001804220-21-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.